MK-677 Long-Term Results: What 2 Years of Trials Actually Show

MK-677 kept IGF-1 elevated for 24 months without a single sign of receptor desensitization. That is the finding from the only two-year double-blind placebo-controlled human trial ever run on this compound. Most MK-677 content online recycles data from 4 to 12-week studies and stops where the interesting data begins. This article covers what the full long-term record actually shows, what it does not show, and what your genetics change about the math before you commit to a year-long protocol.

MK-677 is an oral ghrelin mimetic. It binds GHSR1a, the same receptor that ghrelin stimulates, and triggers pulsatile GH release from the pituitary. Unlike injectable GH, it does not suppress your body's own GH production. Unlike ipamorelin or GHRP-2, you swallow it. That combination of oral bioavailability and endogenous GH stimulation made it the most-studied non-injectable GH secretagogue in clinical research history.

The long-term question has always been: does the effect hold, or does it fade the way hexarelin does in two weeks? The Nass data answers that. The Adunsky data, from a different 2011 trial, introduces a safety caveat that most review articles quietly omit. Both belong in your protocol decision.

What Happens in the First 90 Days of MK-677

The earliest human pharmacology data on MK-677 comes from Chapman and colleagues, published in the Journal of Clinical Endocrinology and Metabolism in 1996. They administered 25 mg daily to healthy older adults and measured 24-hour GH profiles at baseline and after two months of treatment. Mean 24-hour GH rose 97% from baseline. The increase was driven by higher pulse amplitude, not increased pulse frequency. The GH pulse architecture stayed physiological.

That architecture distinction matters. MK-677 does not produce a GH drip the way continuous infusion does. It amplifies the natural pulsatile pattern. Most endocrinologists consider the pulsatile pattern more favorable for receptor sensitivity and for the liver's ability to generate IGF-1 without chronic desensitization. The result: IGF-1 typically rises within 2 to 4 weeks of starting 25 mg daily, and most users notice improved sleep quality in the same window, driven by enhanced slow-wave sleep.

The first two to three weeks also bring fluid retention. This is a known GH-mediated effect. Kidneys express GH receptors, and higher GH signals them to retain sodium. Most users lose the extra fluid by week four as the kidneys adapt. Persistent edema beyond a month is a signal to reduce dose. Running through it without addressing the underlying cause is how people end up with worsening fluid retention over longer cycles.

What the 12-Month Body Composition Data Actually Shows

The Nass 2008 trial measured body composition by DEXA at 12 months. The MK-677 group gained 1.1 kg of lean mass while the placebo group lost 0.5 kg. Net difference: 1.6 kg in favor of MK-677. Not transformative, but real, statistically significant, and directionally consistent with what GH axis activation produces in older adults who are not in a caloric surplus or structured resistance training program.

Here is the part most guides omit: muscle function did not improve. Handgrip strength, stair-climbing power, and walking speed did not differ between groups at 12 months. The lean mass gain appeared on the scale but not in functional performance metrics. This exact dissociation has been documented in exogenous GH trials in older adults repeatedly. The implication for younger, active users is that MK-677 alone, without progressive resistance training, is unlikely to produce the strength and performance gains the forums describe. The studies that show meaningful functional gains pair the compound with training. Protocol design matters as much as the molecule.

Fat mass declined modestly in the MK-677 group. LDL cholesterol fell by approximately 0.14 mmol/L (about 5 mg/dL), a small but directionally consistent effect. Neither finding was the headline result, but both add to the picture of a compound with genuine if moderate metabolic effects at 12 months.

Does MK-677 Stop Working After a Few Months?

This is the question every long-term MK-677 user eventually asks. The answer from the only two-year RCT: no. At 25 mg/day, GHSR1a does not functionally desensitize over a two-year treatment period. IGF-1 at month 24 was statistically equivalent to IGF-1 at month 1. The receptor remained responsive across the entire follow-up window.

Compare that to hexarelin, the most potent injectable GHRP in the research pipeline. GH responsiveness begins attenuating within 7 to 14 days of daily hexarelin dosing. GHRP-2 shows meaningful desensitization in most users within 8 to 12 weeks. MK-677, at standard oral doses, follows neither trajectory.

"Serum IGF-1 concentrations remained significantly elevated in the MK-677 group at the 24-month time point relative to placebo, with no statistically significant attenuation between the 12- and 24-month assessments, suggesting that the pituitary response to MK-677 was maintained without tachyphylaxis at the dose and duration studied."

Nass et al., Annals of Internal Medicine, 2008

Why MK-677 resists desensitization at therapeutic doses is not fully settled. The leading hypothesis: because MK-677 amplifies pulsatile secretion rather than tonically stimulating GHSR1a throughout the day, the receptor has inter-pulse windows to resensitize. Hexarelin and GHRP-2 at high doses produce more sustained receptor occupancy and do not allow that reset. MK-677's 5 to 6 hour plasma half-life, combined with once-daily dosing, creates a pattern that seems to preserve receptor sensitivity over time. This is the pharmacological argument for once-daily evening dosing rather than splitting into two smaller doses.

The Safety Signal Nobody Talks About

In 2011, Adunsky and colleagues published a multicenter Phase IIb trial in Archives of Gerontology and Geriatrics. They enrolled 123 elderly patients recovering from hip fracture (mean age approximately 80) and randomized them to 25 mg/day MK-677 or placebo for 24 weeks. The primary endpoint was functional recovery. The trial was terminated early by the safety monitoring board.

Congestive heart failure occurred in 6.5% of the MK-677 group versus 1.7% on placebo. That is roughly a 3.8-fold increase in one of the most serious cardiovascular events possible in a frail elderly population. The termination was warranted.

This result requires context before it produces panic. The Adunsky population was already at extremely high baseline cardiovascular risk: octogenarians recovering from a hip fracture, likely with comorbid hypertension, chronic kidney disease, and pre-existing cardiac dysfunction. The GH-induced fluid retention that MK-677 reliably produces in the first weeks of use could plausibly tip a compensated cardiac patient into decompensation. The Nass trial in a healthier elderly cohort did not show a cardiac signal.

That context does not make the signal disappear. The FDA cited the Adunsky cardiac findings in its December 2025 warning letters about ibutamoren-containing products. Anyone with existing heart failure, reduced ejection fraction, chronic edema, or significant hypertension should treat MK-677 as contraindicated, not merely as something to approach cautiously.

Why MK-677 and Insulin Resistance Are a Bad Pairing

Growth hormone is counter-regulatory to insulin. It stimulates hepatic glucose output and blunts insulin-mediated glucose uptake in peripheral tissues. This is why untreated acromegaly (a GH-secreting pituitary tumor) causes diabetes in a meaningful proportion of patients. MK-677 raises GH substantially, and the hepatic and peripheral consequences follow.

In the Nass 2008 trial, fasting glucose rose approximately 0.28 mmol/L (about 5 mg/dL) in the MK-677 group over 12 months. Insulin sensitivity, measured by HOMA-IR, declined proportionally. These are modest effects in a population that started metabolically normal. In someone who begins a cycle with fasting glucose already at 95 to 99 mg/dL, or with clinically elevated HOMA-IR, those modest effects can push the numbers out of the healthy range.

The practical protocol: run a fasting glucose and HbA1c before you start. Recheck at 6 to 8 weeks. If you are already tracking bloodwork for IGF-1 timing, pull the full metabolic panel at the same draw. Catching a 10 mg/dL glucose creep at eight weeks is a fixable problem. Finding a prediabetes diagnosis a year into a cycle is not.

Bone Density: What the 18-Month Data Actually Found

The question of whether MK-677 protects bone is more complicated than the forums suggest. Murphy and colleagues ran an 18-month RCT in postmenopausal women with osteoporosis, published in the Journal of Clinical Endocrinology and Metabolism in 2001. They tested MK-677 alone, alendronate alone (the most common osteoporosis drug), and the combination.

MK-677 alone did not improve bone mineral density at any site versus placebo over 18 months. It raised osteocalcin (a bone formation marker) by 22% and a bone resorption marker by 41%. Both bone formation and bone resorption accelerated, but net density did not improve because the two effects roughly cancelled. The combination arm with alendronate, which suppresses resorption while MK-677 drives formation, did show a meaningful BMD gain at the femoral neck: +4.2% versus +2.5% for alendronate alone.

The lesson for long-term MK-677 users: do not use it expecting standalone bone protection. The formation signal is real. The resorption signal is real too, and without a bisphosphonate to suppress resorption, the net bone effect appears neutral over 18 months. For fracture risk, the combination approach with medical supervision is what the data supports.

What Happens to Your Gains When You Stop

No published RCT has prospectively characterized the MK-677 washout curve. The week-by-week IGF-1 decay after stopping has never been tracked in a controlled setting. What we can reason from pharmacology: MK-677 has a plasma half-life of 5 to 6 hours. Steady-state plasma levels fall within 24 hours of the last dose. Since the compound works by stimulating endogenous GH secretion rather than directly delivering GH or IGF-1, the system should return to baseline pulsatile GH within days, not weeks.

Clinical expectation from the GH endocrinology literature is IGF-1 normalization within 1 to 2 weeks after stopping. The Nass 2008 crossover design provides indirect evidence: subjects who switched from MK-677 to placebo in year two showed reversal of lean mass gains and IGF-1 elevation. The direction is clear even though the timeline was not the study's focus.

The practical implication: the lean mass you build on MK-677 is not permanent without continuing the compound or maintaining the stimulus through training. The IGF-1 elevation is entirely cycle-dependent. Plan the off-period accordingly, and treat the 2-week washout window as the floor, not the ceiling, for how long recovery takes in a heavier user.

How Your Genetics Change the MK-677 Math

MK-677 is the GH secretagogue category's most genetic-variable compound. The same 25 mg dose can produce an IGF-1 of 180 ng/mL in one person and 340 ng/mL in another. Most of that variance is genetic, not behavioral.

The largest single predictor is the GHR d3 deletion. People who carry two copies of the d3 variant convert GH pulses to IGF-1 roughly 1.5 times more efficiently than full-length GHR carriers. On a standard MK-677 dose, a d3 homozygote can push IGF-1 well above the reference range without feeling any subjective warning signs. The article on GHR exon 3 deletion and growth peptide response covers this mechanism in detail and explains how to identify which tier you are in before committing to a cycle.

The second major variable is GHSR function. Loss-of-function variants in GHSR1a reduce the GH pulse response to any ghrelin mimetic, including MK-677. If you have seen no response to ipamorelin or GHRP-2 at adequate doses, MK-677 binds the same receptor and will follow the same blunted pattern. Understanding whether your GHSR is the bottleneck is the difference between identifying a non-responding genotype early and spending months on a protocol that was never going to work for you. For the comparison of which GH peptides bypass versus depend on GHSR, the tesamorelin vs MK-677 vs CJC-1295 article covers the receptor-by-receptor breakdown.

Third is IGFBP-3. This binding protein determines how much circulating IGF-1 is biologically active. Total IGF-1 is the measurement that comes back on a standard blood panel. Bioavailable IGF-1, which is what actually reaches your tissues, depends on IGFBP-3 levels. Two users with the same total IGF-1 on MK-677 can have meaningfully different muscle and recovery responses if their IGFBP-3 genetics diverge. If you track bloodwork and your IGF-1 looks solid but results feel flat, the IGFBP-3 explanation deserves investigation before you increase the dose.

For a complete picture of where MK-677 fits in your protocol and how your DNA changes the priority ranking, see the MK-677 peptide profile. The genetic matching score on our report accounts for GHR d3, GHSR function, and IGFBP-3 in the same calculation.